Exploring biologically relevant chemical space with metal complexes.

Altering biological processes with small synthetic molecules is a general approach for the design of drugs and molecular probes. Medicinal chemistry and chemical biology are focused predominately on the design of organic molecules, whereas inorganic compounds find applications mainly for their reactivity (e.g. cisplatin as a DNA-reactive therapeutic) or imaging properties (e.g. gadolinium complexes as MRI diagnostics). In such inorganic pharmaceuticals or probes, coordination chemistry in the biological environment or at the target site lies at the heart of their modes of action. However, past and very recent results suggest that it is also worth exploring a different aspect of metal complexes: their ability to form structures with unique and defined shapes for the design of 'organic-like' small-molecule probes and drugs. In such metal-organic compounds, the metal has the main purpose to organize the organic ligands in three-dimensional space. It is likely that such an approach will complement the molecular diversity of organic chemistry in the quest for the discovery of compounds with superior biological activities.

[1]  F. P. Dwyer,et al.  The Metabolic Fate of Tris-1,10-Phenanthroline 106Ruthenium (II) Perchlorate, a Compound With Anticholinesterase and Curare-Like Activity , 1957 .

[2]  J. Fontecilla-Camps,et al.  Crystallographic and spectroscopic evidence for high affinity binding of FeEDTA(H2O)- to the periplasmic nickel transporter NikA. , 2005, Journal of the American Chemical Society.

[3]  Roy K. Horn,et al.  Technetium-99m-Labeled Receptor-Specific Small-Molecule Radiopharmaceuticals: Recent Developments and Encouraging Results , 1997 .

[4]  Douglas S. Williams,et al.  Switching on a signaling pathway with an organoruthenium complex. , 2005, Angewandte Chemie.

[5]  J. Katzenellenbogen,et al.  Heterodimeric Bis(amino thiol) Complexes of Oxorhenium(V) That Mimic the Structure of Steroid Hormones. Synthesis and Stereochemical Issues. , 1996, The Journal of organic chemistry.

[6]  F. Durant,et al.  De novo drug design of a new copper chelate molecule acting as HIV-1 protease inhibitor , 1998 .

[7]  P. Sadler,et al.  Medicinal Inorganic Chemistry , 1999 .

[8]  F. Cotton,et al.  Basic Inorganic Chemistry , 1976 .

[9]  Eric Meggers,et al.  Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. , 2006, Journal of the American Chemical Society.

[10]  N. Metzler‐Nolte,et al.  Bioorganometallic chemistry of ferrocene. , 2004, Chemical reviews.

[11]  A. Mouithys-Mickalad,et al.  Metal-organic compounds: a new approach for drug discovery. N1-(4-methyl-2-pyridyl)-2,3,6-trimethoxybenzamide copper(II) complex as an inhibitor of human immunodeficiency virus 1 protease. , 2002, Biochemical pharmacology.

[12]  J. Katzenellenbogen,et al.  Selective formation of heterodimeric bis-bidentate aminothiol-oxometal complexes or rhenium(V) , 1993 .

[13]  H. Bregman,et al.  Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety. , 2006, Organic letters.

[14]  Douglas S. Williams,et al.  An organometallic inhibitor for glycogen synthase kinase 3. , 2004, Journal of the American Chemical Society.

[15]  P. Sadler,et al.  Anti-viral cyclam macrocycles : rapid zinc uptake at physiological pH. , 2004, Chemical communications.

[16]  F. P. Dwyer,et al.  The biological actions of 1,10-phenanthroline and 2,2'-bipyridine hydrochlorides, quaternary salts and metal chelates and related compounds. 1. Bacteriostatic action on selected gram-positive, gram-negative and acid-fast bacteria. , 1969, The Australian journal of experimental biology and medical science.

[17]  E. Mayhew,et al.  Inhibition of Landschütz Ascites Tumour Growth by Metal Chelates Derived from 3,4,7,8-Tetramethyl-1,10-phenanthroline , 1965, British Journal of Cancer.

[18]  V. Rapić,,et al.  Helically chiral ferrocene peptides containing 1'-aminoferrocene-1-carboxylic acid subunits as turn inducers. , 2006, Chemistry.

[19]  A. Vessières,et al.  Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates. , 2005, Angewandte Chemie.

[20]  F. P. Dwyer,et al.  Effect of Inorganic Complex Ions on Transmission at a Neuromuscular Junction , 1957, Nature.

[21]  M. Abrams,et al.  Medicinal inorganic chemistry: introduction. , 1999, Chemical reviews.

[22]  G. E. Atilla‐Gokcumen,et al.  Organometallic Compounds with Biological Activity: A Very Selective and Highly Potent Cellular Inhibitor for Glycogen Synthase Kinase 3 , 2006, Chembiochem : a European journal of chemical biology.

[23]  A. Schuffenhauer,et al.  Charting biologically relevant chemical space: a structural classification of natural products (SCONP). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Leclercq,et al.  The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer. , 2004, Current medicinal chemistry.

[25]  S. Knapp,et al.  Ruthenium half-sandwich complexes bound to protein kinase Pim-1. , 2006, Angewandte Chemie.

[26]  B Clotet,et al.  Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. , 1999, Molecular pharmacology.

[27]  F. P. Dwyer,et al.  Biological Activity of Complex Ions , 1952, Nature.

[28]  Simon Parsons,et al.  Protein recognition of macrocycles: binding of anti-HIV metallocyclams to lysozyme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Vessières,et al.  Ferrocenyl hydroxytamoxifen: a prototype for a new range of oestradiol receptor site-directed cytotoxics , 1996 .